Hypoxia-specific gene expression for ischemic disease gene therapy

Hyun Ah Kim, Ram I. Mahato, Minhyung Lee

Research output: Contribution to journalReview article

29 Citations (Scopus)

Abstract

Gene therapy for ischemic diseases has been developed with various growth factors and anti-apoptotic genes. However, non-specific expression of therapeutic genes may induce deleterious side effects such as tumor formation. Hypoxia-specific regulatory systems can be used to regulate transgene expression in hypoxic tissues, in which gene expression is induced in ischemic tissues, but reduced in normal tissues by transcriptional, translational or post-translational regulation. Since hypoxia-inducible factor 1 (HIF-1) activates transcription of genes in hypoxic tissues, it can play an important role in the prevention of myocardial and cerebral ischemia. Hypoxia-specific promoters including HIF-1 binding sites have been used for transcriptional regulation of therapeutic genes. Also, hypoxia-specific untranslated regions (UTRs) and oxygen dependent degradation (ODD) domains have been investigated for translational and post-translational regulations, respectively. Hypoxia-specific gene expression systems have been applied to various ischemic disease models, including ischemic myocardium, stroke, and injured spinal cord. This review examines the current status and future challenges of hypoxia-specific systems for safe and effective gene therapy of ischemic diseases.

Original languageEnglish (US)
Pages (from-to)614-622
Number of pages9
JournalAdvanced Drug Delivery Reviews
Volume61
Issue number7-8
DOIs
StatePublished - Jul 2 2009

Fingerprint

Genetic Therapy
Gene Expression
Hypoxia-Inducible Factor 1
Genes
Untranslated Regions
Brain Ischemia
Transgenes
Myocardial Ischemia
Spinal Cord
Intercellular Signaling Peptides and Proteins
Myocardium
Stroke
Binding Sites
Hypoxia
Oxygen
Therapeutics
Neoplasms

Keywords

  • Gene regulation
  • Gene therapy
  • Hypoxia response element
  • Ischemic disease
  • Oxygen dependent degradation domain
  • Untranslated region

ASJC Scopus subject areas

  • Pharmaceutical Science

Cite this

Hypoxia-specific gene expression for ischemic disease gene therapy. / Kim, Hyun Ah; Mahato, Ram I.; Lee, Minhyung.

In: Advanced Drug Delivery Reviews, Vol. 61, No. 7-8, 02.07.2009, p. 614-622.

Research output: Contribution to journalReview article

Kim, Hyun Ah ; Mahato, Ram I. ; Lee, Minhyung. / Hypoxia-specific gene expression for ischemic disease gene therapy. In: Advanced Drug Delivery Reviews. 2009 ; Vol. 61, No. 7-8. pp. 614-622.
@article{f24d69a4f7d6436e970585bc7bde9e64,
title = "Hypoxia-specific gene expression for ischemic disease gene therapy",
abstract = "Gene therapy for ischemic diseases has been developed with various growth factors and anti-apoptotic genes. However, non-specific expression of therapeutic genes may induce deleterious side effects such as tumor formation. Hypoxia-specific regulatory systems can be used to regulate transgene expression in hypoxic tissues, in which gene expression is induced in ischemic tissues, but reduced in normal tissues by transcriptional, translational or post-translational regulation. Since hypoxia-inducible factor 1 (HIF-1) activates transcription of genes in hypoxic tissues, it can play an important role in the prevention of myocardial and cerebral ischemia. Hypoxia-specific promoters including HIF-1 binding sites have been used for transcriptional regulation of therapeutic genes. Also, hypoxia-specific untranslated regions (UTRs) and oxygen dependent degradation (ODD) domains have been investigated for translational and post-translational regulations, respectively. Hypoxia-specific gene expression systems have been applied to various ischemic disease models, including ischemic myocardium, stroke, and injured spinal cord. This review examines the current status and future challenges of hypoxia-specific systems for safe and effective gene therapy of ischemic diseases.",
keywords = "Gene regulation, Gene therapy, Hypoxia response element, Ischemic disease, Oxygen dependent degradation domain, Untranslated region",
author = "Kim, {Hyun Ah} and Mahato, {Ram I.} and Minhyung Lee",
year = "2009",
month = "7",
day = "2",
doi = "10.1016/j.addr.2009.04.009",
language = "English (US)",
volume = "61",
pages = "614--622",
journal = "Advanced Drug Delivery Reviews",
issn = "0169-409X",
publisher = "Elsevier",
number = "7-8",

}

TY - JOUR

T1 - Hypoxia-specific gene expression for ischemic disease gene therapy

AU - Kim, Hyun Ah

AU - Mahato, Ram I.

AU - Lee, Minhyung

PY - 2009/7/2

Y1 - 2009/7/2

N2 - Gene therapy for ischemic diseases has been developed with various growth factors and anti-apoptotic genes. However, non-specific expression of therapeutic genes may induce deleterious side effects such as tumor formation. Hypoxia-specific regulatory systems can be used to regulate transgene expression in hypoxic tissues, in which gene expression is induced in ischemic tissues, but reduced in normal tissues by transcriptional, translational or post-translational regulation. Since hypoxia-inducible factor 1 (HIF-1) activates transcription of genes in hypoxic tissues, it can play an important role in the prevention of myocardial and cerebral ischemia. Hypoxia-specific promoters including HIF-1 binding sites have been used for transcriptional regulation of therapeutic genes. Also, hypoxia-specific untranslated regions (UTRs) and oxygen dependent degradation (ODD) domains have been investigated for translational and post-translational regulations, respectively. Hypoxia-specific gene expression systems have been applied to various ischemic disease models, including ischemic myocardium, stroke, and injured spinal cord. This review examines the current status and future challenges of hypoxia-specific systems for safe and effective gene therapy of ischemic diseases.

AB - Gene therapy for ischemic diseases has been developed with various growth factors and anti-apoptotic genes. However, non-specific expression of therapeutic genes may induce deleterious side effects such as tumor formation. Hypoxia-specific regulatory systems can be used to regulate transgene expression in hypoxic tissues, in which gene expression is induced in ischemic tissues, but reduced in normal tissues by transcriptional, translational or post-translational regulation. Since hypoxia-inducible factor 1 (HIF-1) activates transcription of genes in hypoxic tissues, it can play an important role in the prevention of myocardial and cerebral ischemia. Hypoxia-specific promoters including HIF-1 binding sites have been used for transcriptional regulation of therapeutic genes. Also, hypoxia-specific untranslated regions (UTRs) and oxygen dependent degradation (ODD) domains have been investigated for translational and post-translational regulations, respectively. Hypoxia-specific gene expression systems have been applied to various ischemic disease models, including ischemic myocardium, stroke, and injured spinal cord. This review examines the current status and future challenges of hypoxia-specific systems for safe and effective gene therapy of ischemic diseases.

KW - Gene regulation

KW - Gene therapy

KW - Hypoxia response element

KW - Ischemic disease

KW - Oxygen dependent degradation domain

KW - Untranslated region

UR - http://www.scopus.com/inward/record.url?scp=65749109731&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65749109731&partnerID=8YFLogxK

U2 - 10.1016/j.addr.2009.04.009

DO - 10.1016/j.addr.2009.04.009

M3 - Review article

C2 - 19394379

AN - SCOPUS:65749109731

VL - 61

SP - 614

EP - 622

JO - Advanced Drug Delivery Reviews

JF - Advanced Drug Delivery Reviews

SN - 0169-409X

IS - 7-8

ER -